Drug profile · INN
zavegepant hydrochloride
ZAVZPRET
zavegepant hydrochloride (ZAVZPRET) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: nasal. Current US regulatory status: approved.
Drug details — zavegepant hydrochloride
- US status
- approved
- Class
- —
- Route
- NASAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
zavegepant hydrochloride (ZAVZPRET) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Mechanism of action
Calcitonin gene-related peptide type 1 receptor antagonist
Primary target: Calcitonin gene-related peptide type 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is zavegepant hydrochloride?
zavegepant hydrochloride (ZAVZPRET) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for zavegepant hydrochloride?
ZAVZPRET is a marketed brand name for zavegepant hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zavegepant hydrochloride?
zavegepant hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.